Innate Pharma Stock Forecast

Stock Price Forecast

The 1 analyst with a 12-month price forecast for Innate Pharma stock has a target of 11.5, which predicts an increase of 413.39% from the current stock price of 2.24.

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$11.5	$11.5	$11.5	$11.5
Change	+413.39%	+413.39%	+413.39%	+413.39%

Analyst Ratings

According to 1 stock analyst, the rating for Innate Pharma is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Sep '24	Oct '24	Nov '24	Dec '24	Jan '25	Feb '25
Strong Buy	1	1	1	1	1	1
Buy	0	0	0	0	0	0
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	1	1	1	1	1	1

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Swayampakula Ramakanth HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $12	Strong Buy	Reiterates	$12	+413.39%	Feb 6, 2025
Swayampakula Ramakanth HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $12	Strong Buy	Reiterates	$12	+413.39%	Jan 17, 2025
Swayampakula Ramakanth HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $12	Strong Buy	Reiterates	$12	+413.39%	Dec 9, 2024
Swayampakula Ramakanth HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $12	Strong Buy	Reiterates	$12	+413.39%	Nov 15, 2024
Swayampakula Ramakanth HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $12	Strong Buy	Reiterates	$12	+413.39%	Nov 12, 2024

More Analyst Ratings

Financial Forecast

Revenue This Year

33.34M

from 61.64M

-45.91%

from 61.64M

Revenue Next Year

64.48M

from 33.34M

93.37%

from 33.34M

EPS This Year

-0.38

from -0.09

EPS Next Year

-0.03

from -0.38

Fiscal Year	FY 2019	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2019	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	85.45M	69.77M	24.70M	57.67M	61.64M	33.34M	64.48M	117.25M
Revenue Growth	-9.05%	-18.35%	-64.60%	133.47%	6.88%	-45.91%	93.37%	81.85%
EPS	-0.31	-0.81	-0.66	-0.73	-0.09	-0.38	-0.03	0.28
EPS Growth	-	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-	7.66
No. Analysts	-	-	-	-	-	5	5	5

Financial currency is EUR. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2024	2025	2026
High	78.8M	193.2M	302.4M
Avg	33.3M	64.5M	117.3M
Low	6.9M	6.9M	19.1M

Revenue Growth

Revenue Growth	2024	2025	2026
High	27.8%	479.4%	369.0%
Avg	-45.9%	93.4%	81.9%
Low	-88.9%	-79.4%	-70.4%

EPS Forecast

EPS	2024	2025	2026
High	0.23	1.41	1.88
Avg	-0.38	-0.03	0.28
Low	-0.67	-0.71	-0.74

EPS Growth

EPS Growth	2024	2025	2026
High	-	-	-
Avg	-	-	-
Low	-	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.